[go: up one dir, main page]

ATE99957T1 - Verabreichungsform fuer einen antagonisten von gamma-interferon zur bekaempfung einer ghkassoziierten autoimmunerkrankung. - Google Patents

Verabreichungsform fuer einen antagonisten von gamma-interferon zur bekaempfung einer ghkassoziierten autoimmunerkrankung.

Info

Publication number
ATE99957T1
ATE99957T1 AT88307633T AT88307633T ATE99957T1 AT E99957 T1 ATE99957 T1 AT E99957T1 AT 88307633 T AT88307633 T AT 88307633T AT 88307633 T AT88307633 T AT 88307633T AT E99957 T1 ATE99957 T1 AT E99957T1
Authority
AT
Austria
Prior art keywords
autoimmune disease
ghk
combating
gamma interferon
administration form
Prior art date
Application number
AT88307633T
Other languages
English (en)
Inventor
Chaim O Jacob
Hugh O Mcdevitt
Peter Van Der Meide
Joseph H Holoshitz
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Application granted granted Critical
Publication of ATE99957T1 publication Critical patent/ATE99957T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT88307633T 1987-08-18 1988-08-17 Verabreichungsform fuer einen antagonisten von gamma-interferon zur bekaempfung einer ghkassoziierten autoimmunerkrankung. ATE99957T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8701587A 1987-08-18 1987-08-18
EP88307633A EP0304291B1 (de) 1987-08-18 1988-08-17 Verabreichungsform für einen Antagonisten von Gamma-Interferon zur Bekämpfung einer GHK-assoziierten Autoimmunerkrankung

Publications (1)

Publication Number Publication Date
ATE99957T1 true ATE99957T1 (de) 1994-01-15

Family

ID=22202449

Family Applications (1)

Application Number Title Priority Date Filing Date
AT88307633T ATE99957T1 (de) 1987-08-18 1988-08-17 Verabreichungsform fuer einen antagonisten von gamma-interferon zur bekaempfung einer ghkassoziierten autoimmunerkrankung.

Country Status (7)

Country Link
US (1) US6036956A (de)
EP (1) EP0304291B1 (de)
JP (1) JP2646114B2 (de)
AT (1) ATE99957T1 (de)
AU (1) AU621830B2 (de)
CA (1) CA1335792C (de)
DE (1) DE3887031T2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1335792C (en) * 1987-08-18 1995-06-06 Chaim O. Jacob Method and dosage form using an antagonist to gamma interferon to control mhc-associated autoimmune disease
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US20030229208A1 (en) * 1988-12-28 2003-12-11 Protein Design Labs, Inc. Humanized immunoglobulins
IT1231727B (it) * 1989-08-11 1991-12-21 Enrico Savoldi Peptidi utili per la determinazione e la purificazione di anticorpi anti gamma interferone.
ES2092698T3 (es) * 1991-08-30 1996-12-01 Genentech Inc Metodo terapeutico para el tratamiento de la diabetes mellitus dependiente de insulina (iddm).
US5888511A (en) * 1993-02-26 1999-03-30 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS
US5624895A (en) * 1994-02-18 1997-04-29 Georgetown University Medical Center Treatment and/or prevention of type I diabetes mellitus with gamma interferon administration
US20020025316A1 (en) 1995-08-18 2002-02-28 Ferguson Mark Williams James Pharmaceutical composition containing inhibitors of interferon-gamma
GB2304342A (en) * 1995-08-18 1997-03-19 Univ Manchester Pharmaceutical comprising either an inhibitor or a stimulator of interferon gamma
US6348495B1 (en) 1996-06-06 2002-02-19 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Method for treating celiac disease
US20030223995A1 (en) * 1996-12-23 2003-12-04 Advanced Biotherapy, Inc. Treatment of pemphigus vulgaris
DE69927520T2 (de) 1998-12-09 2006-06-22 Protein Design Labs, Inc., Fremont Verwendung von il-12 antikörpern zur behandlung von psoriasis
AU2001254726A1 (en) * 2000-03-24 2001-10-03 Micromet Ag Restenosis treatment
US6861056B2 (en) * 2001-06-05 2005-03-01 Advanced Biotherapy, Inc. Compositions and methods for treating hyperimmune response in the eye
WO2004034988A2 (en) * 2002-10-16 2004-04-29 Amgen Inc. Human anti-ifn-ϝ neutralizing antibodies as selective ifn-ϝ pathway inhibitors
EP1582216A4 (de) * 2002-12-26 2010-04-21 Asubio Pharma Co Ltd Heilmittel für pemphigoid
CA2553035A1 (en) 2004-02-02 2005-08-18 Ambrx, Inc. Modified human growth hormone polypeptides and their uses
SG188143A1 (en) 2008-02-08 2013-03-28 Ambrx Inc Modified leptin polypeptides and their uses
CN103169966B (zh) * 2013-04-09 2015-04-01 中国人民解放军军事医学科学院基础医学研究所 一种治疗系统性红斑狼疮的药物组合物
CN103977401B (zh) * 2013-04-09 2016-08-03 中国人民解放军军事医学科学院基础医学研究所 一种治疗多发性硬化的药物组合物
US10436991B2 (en) 2017-05-19 2019-10-08 Adolite Inc. Optical interconnect modules based on glass substrate with polymer waveguide

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1982001773A1 (en) * 1980-11-07 1982-05-27 Secher David S Assay for interferon
US4362155A (en) * 1981-03-24 1982-12-07 Skurkovich Simon V Method and apparatus for the treatment of autoimmune and allergic diseases
US4599306A (en) * 1983-04-15 1986-07-08 Amgen Monoclonal antibodies which specifically bind to human immune interferon
US4666865A (en) * 1984-01-13 1987-05-19 Centocor, Inc. Immunoassay for biologically active human interferon-gamma employing unique monoclonal antibodies
US5336489A (en) * 1985-09-05 1994-08-09 The Beth Israel Hospital Association Treatment of allograft rejection with IL-2 receptor-specific cytotoxins
JPH0742235B2 (ja) * 1985-11-08 1995-05-10 三共株式会社 自己免疫性疾病の予防・治療剤
GB8608068D0 (en) * 1986-04-02 1986-05-08 Cobbold S P Monoclonal antibodies
IL78444A (en) * 1986-04-08 1992-05-25 Yeda Res & Dev Human gamma interferon-specific receptor protein,antibody against said protein,and compositions containing said protein and antibody
US4920097A (en) * 1986-05-28 1990-04-24 Imreg, Inc. Immunosuppressor and method of extraction thereof from leukocytes
KR880701108A (ko) * 1986-06-30 1988-07-25 원본미기재 면역조절 조성물 및 이들의 용도
JPH0621072B2 (ja) * 1986-11-12 1994-03-23 呉羽化学工業株式会社 エストラジオ−ル誘導体よりなる免疫調節剤
US5571500A (en) * 1987-06-24 1996-11-05 Autoimmune, Inc. Treatment of autoimmune diseases through administration by inhalation of autoantigens
US5571499A (en) * 1987-06-24 1996-11-05 Autoimmune, Inc. Treatment of autoimmune diseases by aerosol administration of autoantigens
CA1335792C (en) * 1987-08-18 1995-06-06 Chaim O. Jacob Method and dosage form using an antagonist to gamma interferon to control mhc-associated autoimmune disease
US4908387A (en) * 1988-06-06 1990-03-13 The Regents Of The University Of California Use of beta2 antagonists in the treatment of inflammatory diseases, in particular, rheumatoid arthritis
CA2164641A1 (en) * 1993-06-07 1994-12-22 Dinah S. Singer Use of an mhc class i suppressor drug for the treatment of autoimmune diseases and transplantation rejection
US5695785A (en) * 1996-06-27 1997-12-09 Masonic Medical Research Laboratory Kidney extract for treatment of systematic lupus erythematosus

Also Published As

Publication number Publication date
AU621830B2 (en) 1992-03-26
EP0304291A1 (de) 1989-02-22
EP0304291B1 (de) 1994-01-12
DE3887031D1 (de) 1994-02-24
JP2646114B2 (ja) 1997-08-25
DE3887031T2 (de) 1994-04-28
US6036956A (en) 2000-03-14
JPH01156927A (ja) 1989-06-20
CA1335792C (en) 1995-06-06
AU2112288A (en) 1989-02-23

Similar Documents

Publication Publication Date Title
ATE99957T1 (de) Verabreichungsform fuer einen antagonisten von gamma-interferon zur bekaempfung einer ghkassoziierten autoimmunerkrankung.
Nakamura et al. Effect of IFN-γ on the immune response in vivo and on gene expression in vitro
DE69033700D1 (de) Il-11 aus säugetier
DK0911033T3 (da) Anvendelse af konsensusinterferon til reduktion af bivirkningerne af interferonbehandling i viral hepatitis
ATE415173T1 (de) Pan dr-bindeproteinen zur erhöhung der immunantwort
PT702560E (pt) Intensificacao imunologica com terapia intermitente de interleucina-2
FI822279A7 (fi) Tulehdus- ja immuunisairauksiin ja sileiden lihasten spasmien yhteydessä esiintyviin sairauksiin käytettäkäytettävät farmaseuttiset koostumukset.
DE3880766D1 (de) Konjugate von interferon alpha mit immunglobulinen.
SE7514589L (sv) Aminosyrapreparat for patienter med leversjukdom och sett att anvenda dessa preparat
GB2255093A (en) Hiv-1 core protein fragments
Friedman et al. Reactivation of immunocompetence in spleen cells of aged mice
EP0090581A3 (de) Kleine, für Maul- und Klauenseuche spezifische Peptide
GB1499035A (en) Antistaphylococcus human immune globulin and method of preparing same
DE69213943D1 (de) Kurzzeitige stimulierung von lymphozyten mit anti-cd3 antikörpern um ihre in vivo aktivität zu steigern
DE69233607D1 (de) Peptide, die die zytotoxische T-Lymphozyte Antwort gegen Hepatitis-B-Virus induzieren
EP0222310A3 (de) Verfahren zur Diagnose von Multiple-Sklerose
FI875245A0 (fi) Foerfarande foer oekande av utsoendringen av adenosin.
NO964200L (no) Behandling av autoimmun sykdom ved anvendelse av oral tolerisering og/eller Th2-forsterkende cytokiner
NO964199L (no) Behandling av autoimmun sykdom ved anvendelse av oral tolerisering og/eller type I interferon
Thong et al. Immunopotentiation by pyrimethamine in the mouse
EP0642333A4 (de) Verfahren und zusammensetzungen zur behandlung von krankheiten verbunden mit mangelhaften immunfunktion.
EP0254845A3 (de) Immun-Stimulation mit Chondroitin-sulfat
ATE205397T1 (de) Natürliches menschliches alpha interferon enthaltende pharmazeutische zusammensetzungen
OA08768A (fr) Traitement du virus su SIDA par l'interféron alpha humain recombinant.
RU96114547A (ru) Способ повышения активности систем неспецифической биологической защиты организма

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties